시장보고서
상품코드
1484941

세계의 CT/NG 검사 시장 보고서(2024년)

Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

CT/NG 검사 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2028년에는 CAGR 11.0%로 전망되며, 30억 달러로 성장이 예상됩니다. 향후 예상되는 성장은 원격의료 및 원격의료 서비스의 이용 증가, 맞춤형 의료 접근의 채용, 포인트 오브 케어 검사의 확대, 집단 건강 관리 전략의 실시에 기인하고 있습니다. 이 기간에 예상되는 주요 동향에는 신속한 포인트 오브 케어 검사 기능 확대, 개인화 검사 접근법 도입, 다중 질환 검사 플랫폼 개발, 지역 기반 검사 및 아웃리치 프로그램 확대가 포함됩니다.

성감염증(STI)의 만연 확대는 당면 CT/NG 검사 시장의 확대를 견인할 것으로 예상됩니다. 성 감염은 성적 접촉을 통해 감염되는 박테리아, 바이러스, 기생충에 의한 감염이며, 불충분한 성교육, 성행위의 활성화, 사회적 낙인, 접근 장벽 등의 요인에 의해 증가 경향이 있습니다. CT/NG 검사는 STI 발견 및 관리에 중요한 역할을 하며 조기 진단, 치료 및 감염 예방을 촉진합니다. 예를 들어, 2023년 7월에 세계보건기구(WHO)가 보고한 것처럼, 세계에서는 매일 100만명 이상이 새롭게 STI에 감염되고 있으며, 연간 3억 7,400만명이 새롭게 감염되고 있다고 추정되고 치료 가능한 STI 중 4명 중 1명이 이에 해당합니다. 그 결과 성 감염의 확산은 CTNG 검사 시장의 성장 궤도를 강조합니다.

CT/NG 검사 시장의 주요 기업은 STI와의 싸움을 위한 정확하고 확장 가능한 검사 방법에 대한 요구 증가에 대응하기 위해 혁신적인 검사 솔루션 개발을 선호합니다. 이러한 솔루션 중 하나는 고처리량 감염성 분자진단 플랫폼인 BD COR MX/PX 시스템입니다. 이 정교한 검사 장비는 감염된 병원체에 대한 대량의 시료를 신속하게 분석하도록 설계되었습니다. 2022년 5월 벡톤 디킨슨사에서 출시된 BD COR MX/PX 시스템은 CT 검사 및 NG 검사를 포함한 다수의 감염 검사를 처리하는 실험실 워크플로우를 간소화합니다. 이 플랫폼은 로봇 엔지니어링 및 소프트웨어 알고리즘을 사용하여 전체 검사 프로세스를 자동화하고 효율성을 높이고 검사 결과 대기 시간을 줄일 수 있습니다. 특필해야 할 기능으로는 자동화, 하이 스루풋 기능, 듀얼 DNA 타겟, 모듈식으로 확장 가능한 설계를 들 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나와 러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모 및 성장

  • 세계의 CT/NG 검사 시장 : 촉진요인 및 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 CT/NG 검사 시장 실적 : 규모 및 성장(2018-2023년)
  • 세계의 CT/NG 검사 시장 예측 : 규모 및 성장(2023-2028년, 2033년F)

제6장 시장 세분화

  • 세계의 CT/NG 검사 시장 : 검사 유형별 : 실적 및 예측(2018-2023년, 2023-2028년F, 2033년F)
  • 실험실
  • 포인트 오브 케어 검사
  • 세계의 CT/NG 검사 시장 : 제품별 : 실적 및 예측(2018-2023년, 2023-2028년F, 2033년F)
  • 분석 및 키트
  • 기기 및 분석장치
  • 세계의 CT/NG 검사 시장 : 기술별 : 실적 및 예측(2018-2023년, 2023-2028년F, 2033년F)
  • 등온 핵산 증폭 기술
  • 중합효소 연쇄반응
  • 면역진단
  • 기타 기술
  • 세계의 CT/NG 검사 시장 : 최종 사용자별 : 실적 및 예측(2018-2023년, 2023-2028년F, 2033년F)
  • 진단 실험실
  • 병원 및 진료소
  • 기타 최종 사용자

제7장 지역별 및 국가별 분석

  • 세계의 CT/NG 검사 시장 : 지역별 : 실적 및 예측(2018-2023년, 2023-2028년F, 2033년F)
  • 세계의 CT/NG 검사 시장 : 국가별 : 실적 및 예측(2018-2023년, 2023-2028년F, 2033년F)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

  • CT/NG 검사 시장 : 경쟁 구도
  • CT/NG 검사 시장 : 기업 프로파일
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • Danaher Corporation
    • Merck KGaA

제31장 기타 주요 기업 및 혁신 기업

  • Siemens Healthineers
  • Becton Dickinson and Company
  • Grifols SA
  • Hologic Inc.
  • PerkinElmer
  • bioMerieux
  • Sysmex Corporation
  • Bio-Rad Laboratories
  • QIAGEN
  • Quidel Corporation
  • DiaSorin
  • Cepheid
  • Seegene Inc.
  • Meridian Bioscience Inc.
  • Sekisui Diagnostics

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망 및 잠재적인 분석

제36장 부록

AJY 24.06.05

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing involves diagnosing sexually transmitted infections (STIs) caused by these bacteria in sexually active individuals, particularly those with multiple partners or engaging in unprotected sexual activity. These tests aim to identify the presence of CT and NG bacteria through various methods such as urine samples, genital area swabs, or blood tests.

The primary testing methods for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are laboratory testing and point-of-care testing. Laboratories are specialized facilities equipped with trained personnel and specialized equipment to conduct CT and NG testing on patient samples. This includes a range of products such as assays, kits, instruments, and analyzers utilizing various technologies such as isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, among others. End users of these laboratory services include diagnostic laboratories, hospitals, clinics, and other healthcare facilities.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report is one of a series of new reports from The Business Research Company that provides chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market statistics, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market share, detailed chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry. This chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $1.98 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to several factors, including the emergence of antibiotic resistance, heightened awareness campaigns and educational initiatives, as well as policy changes aimed at addressing the challenges posed by sexually transmitted infections (STIs) such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size is expected to see rapid growth in the next few years. It will grow to $3.00 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. The forecasted growth in the upcoming period can be attributed to the increasing utilization of telemedicine and telehealth services, the adoption of personalized medicine approaches, the expansion of point-of-care testing, and the implementation of population health management strategies. Major trends anticipated in this period encompass the broadening of rapid point-of-care testing capabilities, the implementation of personalized testing approaches, the development of multi-disease testing platforms, and the expansion of community-based testing and outreach programs.

The escalating prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the foreseeable future. STIs, resulting from bacterial, viral, or parasitic infections transmitted through sexual contact, are on the rise due to factors such as inadequate sex education, heightened sexual activity, societal stigma, and accessibility barriers. CT and NG testing plays a crucial role in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For instance, as reported by the World Health Organization in July 2023, over 1 million new STIs are contracted daily worldwide, with an estimated 374 million new infections occurring annually, encompassing one in four treatable STIs. Consequently, the escalating prevalence of sexually transmitted infections underscores the growth trajectory of the CTNG testing market.

Key players in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the development of innovative testing solutions to address the growing need for accurate and scalable testing methods to combat STIs. One such solution is the BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform. This sophisticated laboratory instrument is designed to rapidly analyze large numbers of samples for infectious agents. Launched by Becton Dickinson and Company in May 2022, the BD COR MX/PX System streamlines workflow in labs processing numerous infectious disease tests, including CT and NG testing. The platform automates the entire testing process using robotics and software algorithms, enhancing efficiency and potentially reducing wait times for test results. Notable features include automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

In September 2021, F. Hoffmann-La Roche AG bolstered its molecular diagnostics portfolio by acquiring TIB Molbiol, a Germany-based biotechnology company, for an undisclosed sum. This strategic acquisition enhances Roche's capabilities in molecular diagnostics, particularly in infectious diseases, and broadens its range of tests for existing and emerging pathogens. TIB Molbiol's Lightmix Kit 480 HT CT/NG, a CT/NG testing solution, strengthens Roche's offerings in the STI testing segment, enabling the company to provide innovative diagnostic solutions and improve patient outcomes in the field of infectious diseases.

Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMerieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2023. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

  • Including: 1) By Test Type: Laboratory; Point Of Care Testing
  • 2) By Product: Assays And Kits; Instruments Or Analyzers
  • 3) By Technology: Isothermal Nucleic Acid Amplification Technology; Polymerase Chain Reaction; Immunodiagnostics
  • 4) By End User: Diagnostic Laboratories; Hospitals And Clinics
  • Covering: F. Hoffmann-La Roche AG; Thermo Fisher Scientific; Abbott Laboratories; Danaher Corporation; Merck KGaA

Table of Contents

1. Executive Summary

2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Characteristics

3. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Trends And Strategies

4. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Size and Growth

  • 5.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmentation

  • 6.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Laboratory
  • Point Of Care Testing
  • 6.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Assays And Kits
  • Instruments Or Analyzers
  • 6.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Isothermal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Other Technologies
  • 6.4. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnostic Laboratories
  • Hospitals And Clinics
  • Other End Users

7. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Regional And Country Analysis

  • 7.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 8.1. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 9.1. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 9.2. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 10.1. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 11.1. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 11.2. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 12.1. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 13.1. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 14.1. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 14.2. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 15.1. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 15.2. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 16.1. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 17.1. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 18.1. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 19.1. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 20.1. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 21.1. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 21.2. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 22.1. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 23.1. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 23.2. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 24.1. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 24.2. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 25.1. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 25.2. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 26.1. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 26.2. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 27.1. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 28.1. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 28.2. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 29.1. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 29.2. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape And Company Profiles

  • 30.1. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape
  • 30.2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Abbott Laboratories
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Danaher Corporation
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck KGaA
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Other Major And Innovative Companies

  • 31.1. Siemens Healthineers
  • 31.2. Becton Dickinson and Company
  • 31.3. Grifols SA
  • 31.4. Hologic Inc.
  • 31.5. PerkinElmer
  • 31.6. bioMerieux
  • 31.7. Sysmex Corporation
  • 31.8. Bio-Rad Laboratories
  • 31.9. QIAGEN
  • 31.10. Quidel Corporation
  • 31.11. DiaSorin
  • 31.12. Cepheid
  • 31.13. Seegene Inc.
  • 31.14. Meridian Bioscience Inc.
  • 31.15. Sekisui Diagnostics

32. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Benchmarking

33. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

35. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Future Outlook and Potential Analysis

  • 35.1 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제